M.B. Antsiferov

SBHCI Endocrinological Dispensary of Moscow Healthcare Department
The article discusses the features of the course of diabetes mellitus (DM) in elderly patients, hypoglycemic therapy in which has its own characteristics. The use of antidiabetic drugs with a minimum dose frequency during the day and a low risk of side effects - nephrotoxicity, hepatotoxicity and hypoglycemia - is an important principle of treatment of such patients. Prospects of use of dipeptidyl peptidase-4 inhibitor saxagliptin in elderly patients with type 2 diabetes are considered. Currently, there are 6 international, placebo-controlled studies of efficacy and safety of this drug in DM2 patients over age 65 years. Their results suggest that the therapy with saxagliptin and combination of saxagliptin + metformin in elderly DM2 patients is is sufficiently safe and effective in relation to the risk of hypoglycaemia and cardiovascular events.


  1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta: US Centers for Disease Control and Prevention (Department of Health and Human Services); 2011. Available from: Accessed December 12, 2012.
  2. Soriguer F., Goday А., Bosch-Comas А., Bordiu E., Calle-Pascual A., Carmena R., Casamitjana R., Castano L., Castell C., Catala M., Delgado E., Franch J., Gaztambide S., Girbes J., Gomis R., Gutierrez G., Lopez-Alba A., Martinez-Larrad M.T., Menendez E., Mora-Peces I., Ortega E., Pascual-Manich G., Rojo-Martinez G., Serrano-Rios M., Valdes S., Vazquez J.A., Vendrell J. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Study. Diabetologia. 2012;55(1):88–9.
  3. California Healthcare Foundation / American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for Improving the care of the older person with diabetes mellitus. J. Am. Geriatr. Soc. 2003;51:S265–280.
  4. Sommerfield A.J., Deary I.J., Frier B.M. Acute hyperglycemia alters mood state and impairs cognitive performance in people with type 2 diabetes. Diabetes Care. 2004;27:2335–40.
  5. Air E.L., Kissela B.M. Diabetes, the metabolic syndrome, and ischemic stroke: epidemiology and possible mechanisms. Diabetes Care. 2007;30:31–40.
  6. Auer R.N. Hypoglycemic brain damage. Metab. Brain Dis. 2004;19:169–75.
  7. Kodl C.T., Seaquist E.R. Cognitive dysfunction and diabetes millitus. Endoc. Rev. 2008;29:494–511.
  8. Bruce D.C., Casey G.P., Grange V., Clarnette R.C., Almeida O.P., Foster J.K., Ives F.J., Davis T.M. Cognitive impairment, physical disability and depressive symptoms in older diabetic patients: the Fremantle Cognition in Diabetes Study. Diabetes Res. Clin. Pract. 2003;61:59–67.
  9. van de Vorst I.E., Koek H.L., de Vries R., Bots M.L., Reitsma J.B., Vaartjes I. Effect of Vascular Risk Factors and Diseases on Mortality in Individuals with Dementia: A Systematic Review and Meta-Analysis. J. Am. Geriatr. Soc. 2016;64(1):37–46.
  10. Yaffe K., Blackwell T., Whitmer R.A., Krueger K., Barrett C.E. Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J. Nutr. Health Aging. 2006;10:293–95.
  11. Moghissi E., Ismail-Beigi F., Devine R.C. Hypoglycemia: minimizing its impact in type 2 diabetes. Endocr. Pract. 2013;19(3):526–35.
  12. Huang X., Pan J., Chen D., Chen J., Chen F., Hu T. Efficacy of lifestyle interventions in patients with type 2 diabetes: A systematic review and meta-analysis. Eur. J. Int. Med. 2016;27:37–47.
  13. Jakubowicz D., Wainstein J., Ahren B., Landau Z., Bar-Dayan Y., Froy O. Fasting Until Noon Triggers Increased Postprandial Hyperglycemia and Impaired Insulin Response After Lunch and Dinner in Individuals With Type 2 Diabetes: A Randomized Clinical Trial. Diabetes Care. 2015;38(10):1820–26.
  14. Desai N.R., Shrank W.H., Fischer M.A., Avorn J., Liberman J.N., Schneeweiss S., Pakes J., Brennan T.A., Choudhry N.K. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am. J. Med. 2012;125:302.e1–7.
  15. Karyekar C.S., Ravichandran S., Allen E., Fleming D., Frederich R. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged 65 years) with inadequately controlled type 2 diabetes mellitus. Clin. Interv. Aging. 2013;8:419–30.
  16. Schernthaner G., Duran-Garcia S., Hanefeld M., Langslet G., Niskanen L., Östgren C.J., Malvolti E., Hardy E. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes Obes. Metab. 2015;17(7):630–38.
  17. Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., Ohman P., Frederich R., Wiviott S.D., Hoffman E.B., Cavender M.A., Udell J.A., Desai N.R., Mosenzon O., McGuire D.K., Ray K.K., Leiter L.A., Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 2013;369(14): 1317–26.
  18. Scirica B.M., Braunwald E., Raz I., Cavender M.A., Morrow D.A., Jarolim P., Udell J.A., Mosenzon O., Im K., Umez-Eronini A.A., Pollack P.S., Hirshberg B., Frederich R., Lewis B.S., McGuire D.K., Davidson J., Steg P.G., Bhatt D.L.; SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579–88.
  19. FDA EMDAC Committee Meeting briefing document, April 2014.
  20. Leiter L.A., Teoh H., Braunwald E., Mosenzon O., Cahn A., Kumar K.M., Smahelova A., Hirshberg B., Stahre C., Frederich R., Bonnici F., Scirica B.M., Bhatt D.L., Raz I. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care. 2015;38:1145–53.
  21. Epub ahead of print

About the Autors

M.B. Antsiferov – Doctor of Medical Scineces, Professor, Chief Physician SBHCI "Endocrinological Dispensary" of Moscow Healthcare Department; tel. 8 (499) 246-61-75

Similar Articles

Бионика Медиа